Attached files
file | filename |
---|---|
EX-99.1 - EXHIBIT 99.1 - THERAGENICS CORP | a50563294-ex991.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
______________
FORM
8-K
______________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report: February
14, 2013
THERAGENICS
CORPORATION®
(Exact
name of registrant as specified in charter)
Delaware |
001-14339 |
58-1528626 |
(State of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.) |
5203 Bristol Industrial Way
Buford, Georgia 30518
(Address
of principal executive offices / Zip Code)
(770) 271-0233
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On February 14, 2013, Theragenics Corporation (the “Company”) issued a press release regarding its consolidated financial results for the quarter and year ended December 31, 2012. The Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Theragenics Corporation |
|||
(Registrant) |
|||
Dated: |
February 14, 2013 |
||
|
By: |
/s/ M. Christine Jacobs |
|
M. Christine Jacobs |
|||
Chief Executive Officer |
EXHIBIT INDEX
Exhibit No. |
Description |
99.1 |
Press Release, dated February 14, 2013 of Theragenics Corporation. |